Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers

Cephalalgia

Volumn 17, Issue 6, 1997, Pages 639-646

  Dixon, R M ^a,d   Meire, H B ^b   Evans, D H ^c   Watt, H ^a   On, N ^a   Posner, J ^a   Rolan, P E ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Ergotamine; Migraine; Peripheral vasculature; Pharmacokinetics; Zolmitriptan

Indexed keywords

CAFERGOT; ZOLMITRIPTAN;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOGRAPHY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CAFFEINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERGOTAMINE; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; OXAZOLES; OXAZOLIDINONES; PULSE; REFERENCE VALUES; SEROTONIN AGONISTS; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0030874857     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1706639.x     Document Type: Article

References (31)

1. 1D receptor agonist in the acute treatment of migraine: a double blind, placebo controlled dose range finding study. Neurology 1996;46:1-5
2. Rapoport AM. Optimising the oral dose of 311C90 in the acute treatment of migraine. Cephalalgia 1995;15 Suppl 14:221, abstract P19
3. Seaber ES, On N, Phillips S, Rolan PE, Posner J. The pharmacokinetics and tolerability of the novel antimigraine compound 311C90 in healthy volunteers. Br J Clin Pharmacol 1996;41:141-7
4. Edvinsson L, Jansen I, Olesen J. Analysis of the vasoconstrictor effects of sumatriptan on human cranial arteries. Cephalalgia 1991;11 Suppl 11:210-11
5. 1-like receptor agonist. Br J Pharmacol 1989;96:376-89
6. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-6
7. Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991;12: 144-5
8. 2 receptor activation. Eur J Pharmacol 1989;161:91-4
9. 1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6
10. 1 receptor agonist, on the systemic, pulmonary and coronary circulations. Circulation 1993;87:401-5
11. Sumatriptan Data Sheet
12. Lance JW. Treatment of migraine. Lancet 1992;339:1207-9
13. Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 1986;59:Suppl III
14. Muller-Schweinitzer E, Sturmer E. Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Br J Pharmacol 1974;51:441-6
15. Tfelt-Hansen P, Kanstrup IL, Christensen NJ, Winkler K. General and regional haemodynamic effects of intravenous ergotamine in man. Clin Sci 1983;65:599-604
16. Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol 1980;47:151-6
17. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985;37:29-35
18. Nielsen PE, Bell G, Lassen NA. The measurement of digital systolic blood pressure by strain gauge technique. Scand J Clin Lab Invest 1972;29:371-9
19. Dige-Petersen H, Lassen NA, Noer I, Tonnesen KH. Subclinical ergotism. Lancet 1987:65-6
20. Tfelt-Hansen P, Ostergaard JR, Gothgen I, Jacobsen E, Rasmussen JP, Husum B. Nitro-glycerine for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case. Eur J Clin Pharmacol 1982;22:105-9
21. Dixon RM, Meire HB, Posner J, Rolan PE. Evaluation of non-invasive techniques to assess vasoconstriction by methoxamine in healthy subjects. Cephalalgia 1996;16:507-17
22. Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7:213-16
23. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinetics 1985;10:334-52
24. World MJ. Estimation of cardiac output by bioimpedance cardiography. JR Arm Med Corps 1990;136:92-9
25. Bernstein DP. Continuous non-invasive real-time monitoring of stroke volume and cardiac output by thoracic electrical bioimpedance. Crit Care Med 1986;14:898-901
26. Bernstein DP. A new stroke volume equation for thoracic electrical bioimpedance. Crit Care Med 1986;14:904-9
27. Bell G, Nielsen PE, Lassen NA, Wolfson B. Indirect measurement of systolic blood pressure in the lower limb using a mercury in rubber strain gauge. Cardiovasc Res 1973;7:282-9
28. Otterwanger JP, Stricker BH. Cardiovascular adverse reactions to sumatriptan: cause for concern? CNS Drugs 1995;3:90-8
29. Houghton LA, Foster JM, Whorwell PJ, et al. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994;344:985-6
30. Meire HB, Farrant P. In: Basic ultrasound. Chichester: J Wiley & Sons 1995:62
31. Gosling RG, Dunbar G, King DH, et al. The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique. Angiology 1971;22:52-5